A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

classical hodgkin lymphoma recurrent, classical hodgkin lymphoma refractory, primary mediastinal large b-cell lymphoma recurrent, primary mediastinal large b-cell lymphoma refractory, programmed cell death-1 (pd1, pd-1), programmed death-ligand 1 (pdl1, pd-l1), programmed cell death-2 (pd2, pd-2), programmed death-ligand 2 (pdl2, pd-l2), interventional, phase2